Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9955330 | 1.00 | MEN1 (0.39) | MEN1KMT2ASMN1; SMN2TSHRMAPK1 | |
| SCHEMBL1154318 | 1.00 | MEN1 (0.39) | MEN1KMT2ASMN1; SMN2TSHRMAPK1 | |
| SCHEMBL525920 | 0.96 | — | — | |
| SCHEMBL5558812 | 0.86 | — | — | |
| SCHEMBL16328524 | 0.86 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL24936533 | 0.86 | KDM4E (0.36) | MEN1KMT2ASMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL12143358 | 0.86 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL22515372 | 0.86 | KDM4E (0.36) | MEN1KMT2ASMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL16329702 | 0.86 | ALDH1A1 (0.43) | MEN1KMT2ATSHRALDH1A1RAB9A | |
| SCHEMBL16359227 | 0.86 | MEN1 (0.35) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11564992-B2 | Nucleophilic catalysts for oxime linkage | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-31 | — | — | US | claimed |
| CN-109620963-B | Nucleophilic catalysts for oxime linkage | 武田药品工业株式会社 | 2022-10-28 | — | — | CN | claimed |
| EP-4023247-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | Takeda Pharmaceutical Company Limited (JP) | 2022-07-06 | — | — | EP | claimed |
| EP-4019049-A1 | METHODS FOR PREPARING THERAPEUTIC PROTEIN-POLYMER CONJUGATES | Takeda Pharmaceutical Company Limited (JP) | 2022-06-29 | — | — | EP | claimed |
| EP-3505186-B1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | TAKEDA PHARMACEUTICALS CO (JP) | 2022-01-12 | — | — | EP | claimed |
| US-20210163527-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-03 | — | — | US | claimed |
| US-20200230252-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-23 | — | — | US | claimed |
| US-10576160-B2 | Nucleophilic catalysts for oxime linkage | BAXALTA INCORPORATED (US) | 2020-03-03 | — | — | US | claimed |
| US-10414793-B2 | Nucleophilic catalysts for oxime linkage | BAXALTA INCORPORATED (IL) | 2019-09-17 | — | — | US | claimed |
| US-10350301-B2 | Blood coagulation protein conjugates | BAXALTA INCORPORATED (US) | 2019-07-16 | — | — | US | claimed |
| EP-2459224-B1 | BLOOD COAGULATION PROTEIN CONJUGATES | Baxalta GmbH (CH) | 2016-06-01 | — | — | EP | claimed |
| US-20160120994-A1 | BLOOD COAGULATION PROTEIN CONJUGATES | BAXALTA INC (US) | 2016-05-05 | — | — | US | claimed |
| US-20150024455-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-22 | — | — | US | claimed |
| US-20140121351-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | BAXTER HEALTHCARE SA (CH) | 2014-05-01 | — | — | US | claimed |
| US-8642737-B2 | Nucleophilic catalysts for oxime linkage | BAXTER INTERNATIONAL INC. (US) | 2014-02-04 | — | — | US | claimed |
| US-8637640-B2 | Blood coagulation protein conjugates | BAXTER INTERNATIONAL INC. (US) | 2014-01-28 | — | — | US | claimed |
| US-20130310546-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE AND USE OF NMR ANALYSES OF THE SAME | BAXALTA INCORPORATED | 2013-11-21 | — | — | US | claimed |
| US-20120035344-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | BAXTER HEALTHCARE S.A. (CH) | 2012-02-09 | — | — | US | claimed |
| US-20110028693-A1 | BLOOD COAGULATION PROTEIN CONJUGATES | BAXTER INTERNATIONAL INC. (US) | 2011-02-03 | — | — | US | claimed |
| US-20110027350-A1 | GLYCOPOLYSIALYLATION OF NON-BLOOD COAGULATION PROTEINS | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2011-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414793-B2 | Nucleophilic catalysts for oxime linkage | LPO, OGA, DAO | MEN1 4354/4885KMT2A 2819/4885SMN1; SMN2 2779/4885 |
| US-10576160-B2 | Nucleophilic catalysts for oxime linkage | LPO, OGA, DAO | MEN1 4354/4885KMT2A 2819/4885SMN1; SMN2 2779/4885 |
| US-20120035344-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | LPO, OGA, DAO | MEN1 4354/4885KMT2A 2819/4885SMN1; SMN2 2779/4885 |
| US-10350301-B2 | Blood coagulation protein conjugates | F13B, F12, F2 | MEN1 3815/4885KMT2A 1975/4885SMN1; SMN2 3685/4885 |
| US-11564992-B2 | Nucleophilic catalysts for oxime linkage | LPO, OGA, DAO | MEN1 4354/4885KMT2A 2819/4885SMN1; SMN2 2779/4885 |
| US-20150024455-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | LPO, OGA, DAO | MEN1 4354/4885KMT2A 2819/4885SMN1; SMN2 2779/4885 |
| US-20200230252-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | LPO, OGA, DAO | MEN1 4354/4885KMT2A 2819/4885SMN1; SMN2 2779/4885 |
| US-20130310546-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE AND USE OF NMR ANALYSES OF THE SAME | OGA, LPO, CA12 | MEN1 4305/4885KMT2A 2033/4885SMN1; SMN2 1993/4885 |
| US-20110028693-A1 | BLOOD COAGULATION PROTEIN CONJUGATES | F13B, F12, F2 | MEN1 3815/4885KMT2A 1975/4885SMN1; SMN2 3685/4885 |
| US-20140121351-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | LPO, OGA, DAO | MEN1 4354/4885KMT2A 2819/4885SMN1; SMN2 2779/4885 |
| US-20110027350-A1 | GLYCOPOLYSIALYLATION OF NON-BLOOD COAGULATION PROTEINS | HPSE, GYPA, GBA2 | MEN1 3778/4885KMT2A 1292/4885SMN1; SMN2 1519/4885 |
| US-20210163527-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | LPO, OGA, DAO | MEN1 4354/4885KMT2A 2819/4885SMN1; SMN2 2779/4885 |
| US-20160120994-A1 | BLOOD COAGULATION PROTEIN CONJUGATES | F13B, F12, F2 | MEN1 3815/4885KMT2A 1975/4885SMN1; SMN2 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.